Corrections to in vitro intrinsic clearance-based optimization of N 3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF 1) receptor antagonists (Journal of Medicinal Chemistry (2009) 52, (4161-4172) DOI: 10.1021/jm900302q];In vitro intrinsic clearance-based optimization of N3- phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4161-4172

  Hartz, Richard A ^a   Ahuja, Vijay T ^a   Rafalski, Maria ^a   Schmitz, William D ^a   Brenner, Allison B ^a   Denhart, Derek J ^a   Ditta, Jonathan L ^a   Deskus, Jeffrey A ^a   Yue, Eddy W ^a   Arvanitis, Argyrios G ^a   Lelas, Snjezana ^a   Li, Yu Wen ^a   Molski, Thaddeus F ^a   Wong, Harvey ^a   Grace, James E ^a   Lentz, Kimberley A ^a   Li, Jianqing ^a   Lodge, Nicholas J ^a   Zaczek, Robert ^a   Combs, Andrew P ^a   Olson, Richard E ^a   Mattson, Ronald J ^a   Bronson, Joanne J ^a   Macor, John E ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 CHLORO 2,6 DIMETHYLPHENYLAMINO) 1 (1 CYCLOPROPYLETHYL) 5 METHYLPYRAZIN 2(1H) ONE; 4 (1 CYCLOPROPYLETHYL) 6 [2,6 DICHLORO 4 (DIFLUOROMETHOXY)PHENYLAMINO] 5 OXO 4,5 DIHYDROPYRAZINE 2 CARBONITRILE; 5 CHLORO 1 (1 CYCLOPROPYLETHYL) 3 [2,6 DICHLORO 4 (TRIFLUOROMETHYL)PHENYLAMINO]PYRAZIN 2(1H) ONE; BENZENE DERIVATIVE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING HORMONE RECEPTOR 1 ANTAGONIST; N 3 PHENYLPYRAZINONE DERIVATIVE; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IC 50; IN VITRO STUDY; LIVER MICROSOME; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; STRUCTURE ACTIVITY RELATION;

EID: 67650741974     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9011033     Document Type: Erratum

References (48)

1. Dzierba, C. D.; Hartz, R. A.; Bronson, J. J. Recent advances in corticotropin-releasing factor receptor antagonists. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic: San Diego, 2008; Vol. 43, pp 1-23.
2. Tellew, J. E.; Luo, Z. Small molecule antagonists of the corticotropin-releasing factor (CRF) receptor: recent medicinal chemistry developments. Curr. Top. Med. Chem. 2008, 8, 506-520.
3. Grigoriadis, D. E. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders. Expert Opin. Ther. Targets 2005, 9, 651-684.
4. Gilligan, P. J.; Li, Y.-W. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Curr. Opin. Drug Discovery Dev. 2004, 7, 487-497.
5. Grigoriadis, D. E.; Haddach, M.; Ling, N.; Saunders, J. The CRF receptor: structure, function and potential for therapeutic intervention. Curr. Med. Chem. 2001, 1, 63-97.
6. Gilligan, P. J.; Robertson, D. W.; Zaczek, R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. 2000, 43, 1641-1660.
7. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213, 1394-1397.
8. De Souza, E. B.; Grigoriadis, D. E. Corticotropin-releasing factor: physiology, pharmacology, and role in central nervous system and immune disorders. In Psychopharmacology: The Fourth Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven: New York, 1995; pp 505-517.
9. Owens, M. J.; Nemeroff, C. B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 1991, 43, 425-473.
10. Chen, R.; Lewis, K. A.; Perrin, M. H.; Vale, W. W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8967-8971.
11. Perrin, M. H.; Donaldson, C. J.; Chen, R.; Lewis, K. A.; Vale, W. W. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology 1993, 133, 3058-3061.
12. Chalmers, D. T.; Lovenberg, T. W.; Grigoriadis, D. E.; Behan, D. P.; De Souza, E. B. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 1996, 17, 166-172.
13. Perrin, M.; Donaldson, C.; Chen, R.; Blount, A.; Berggren, T.; Bilezikjian, L.; Sawchenko, P.; Vale, W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2969-2973.
14. Liaw, C. W.; Lovenberg, T. W.; Barry, G.; Oltersdorf, T.; Grigoriadis, D. E.; De Souza, E. B. Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 1996, 137, 72-77.
15. Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999, 33, 181-214.
16. 1 receptor antagonists become antidepressant and/or anxiolytic agents? Drug Dev. Res. 2005, 65, 191-204.
17. O'Brien, D.; Skelton, K. H.; Owens, M. J.; Nemeroff, C. B. Are CRF receptor antagonists potential antidepressants? Hum. Psychopharmacol. Clin. Exp. 2001, 16, 81-87.
18. Dinan, T. G. Novel approaches to the treatment of depression by modulating the hypothalamic-pituitary-adrenal axis. Hum. Psychopharmacol. Clin. Exp. 2001, 16, 89-93.
19. McElroy, J. F.; Ward, K. A.; Zeller, K. L.; Jones, K. W.; Gilligan, P. J.; He, L.; Lelas, S. The CRF1 receptor antagonist DMP696 produces anxiolytic effects and inhibits the stress-induced hypothalamic-pituitary-adrenal axis activation without sedation or ataxia in rats. Psycopharmacology 2002, 165, 86-92.
20. Gilligan, P. J.; Li, Y.-W. Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases. Curr. Opin. Drug Discovery Dev. 2004, 7, 487-497.
21. Mansbach, R. S.; Brooks, E. N.; Chen, Y. L. Antidepressant-like effects of CP-154526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 1997, 323, 21-26.
22. 1 receptors in rats. J. Pharmal. Exp. Ther. 2004, 309, 293-302.
23. Chen, C.; Wilcoxen, K. M.; Huang, C. Q.; Xie, Y.-F.; McCarthy, J. R.; Webb, T. R.; Zhu, Y.-F.; Saunders, J.; Liu, X.-J.; Chen, T.-K.; Bozigian, H.; Grigoriadis, D. E. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7- dipropylaminopyrazolo[1,5-a]-pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J. Med. Chem. 2004, 47, 4787-4798.
24. Zobel, A. W.; Nickel, T.; Kunzel, H. E.; Ackl, N.; Sonntag, A.; Ising, M.; Holsboer, F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000, 34, 171-181.
25. Guo, Z.; Tellew, J. E.; Gross, R. S.; Dyck, B.; Grey, J.; Haddach, M.; Kiankarimi, M.; Lanier, M.; Li, B.-F.; Luo, Z.; McCarthy, J. R.; Moorjani, M.; Saunders, J.; Sullivan, R.; Zhang, X.; Zamani-Kord, S.; Grigoriadis, D. E.; Crowe, P. D.; Chen, T. K.; Williams, J. P. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists. J. Med. Chem. 2005, 48, 5104-5107.
26. Ising, M.; Zimmermann, U. S.; Kunzel, H. E.; Uhr, M.; Foster, A. C.; Learned-Coughlin, S. M.; Holsboer, F.; Grigoriadis, D. E. High-affinity CRF (1) receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 2007, 32, 1941-1949.
27. 1 receptor antagonists. Eur. J. Pharmacol. 2008, 583, 350-357.
28. Chen, Y. L.; Braselton, J.; Forman, J.; Gallaschun, R. J.; Mansbach, R.; Schmidt, A. W.; Seeger, T. F.; Sprouse, J. F.; Tingley, F. D.; Winston, E.; Schulz, D. W. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists. J. Med. Chem. 2008, 51, 1377-1384.
29. Binneman, B.; Feltner, D.; Kolluri, S.; Shi, Y.; Qiu, R.; Stiger, T.A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Amer. J. Psychiatry 2008, 165, 617-620.
30. Chen, Y. L.; Obach, R. S.; Braselton, J.; Corman, M. L.; Forman, J.; Freeman, J.; Gallaschun, R. J.; Mansbach, R.; Schmidt, A. W.; Sprouse, J. S.; Tingley, F. D.,; Winston, E.; Schulz, D. W. 2-Aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J. Med. Chem. 2008, 51, 1385-1392.
31. 1) receptor antagonists. J. Med. Chem. 2009, 52.
32. Arvanitis, A. G.; Olson, R. E.; Arnold, C. R., III; Frietze, W. E. Pyrazinones and triazinones and their derivatives thereof. World Patent Appl. WO 98/11075 A1, 1998. (33) Compound 7 is compound 12p in ref 31.
33. The synthesis of noncommercially available amine hydrochlorides is described in ref 31.
34. Vekemans, J.; Pollers-Wieers, C.; Hoornaert, G.Anew synthesis of substituted 2(1H)-pyrazinones. J. Heterocycl. Chem. 1983, 20, 919-923.
35. Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Daeyaert, F. F. D.; Vinkers, M.; Van Aken, K. J. A.; Arnold, E.; Das, K.; Kilonda, A.; Hoornaert, G. J.; Compernolle, F.; Cegla, M.; Azzam, R. A.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Janssen, P. A. J. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. J. Med. Chem. 2005, 48, 1910-1918.
36. Bekkali, Y.; Cardozo, M. G.; Kirrane, T. M.; Kuzmich, D.; Proudfoot, J. R.; Takahashi, H.; Thompson, D.; Wang, J.; Zindell, R.; Harcken, C. H. J. J.; Razavi, H. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. World Patent Appl. WO 2003 082787-A1, 2003.
37. The general screening strategy outlined in ref 31 was used, wherein the experimental procedures for the CRF binding assay, functional assay (Y-79 cells), protein binding studies, and behavioral studies are described.
38. 2,6-Dichloro-4-methoxyaniline was prepared according to the procedure in Kenny, J. R.; Maggs, J. L.; Meng, X.; Sinnott, D.; Clarke, S. E.; Park, K. B.; Stachulski, A. V. Syntheses and characterization of the acyl glucuronide and hydroxy metabolites of diclofenac. J. Med. Chem. 2004, 47, 2816-2825.
39. Erickson, J. A.; McLoughlin, J. I. Hydrogen bond donor properties of the difluoromethyl group. J. Org. Chem., 1995, 60, 1626-1631.
40. 1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 2002, 12, 701-704.
41. 2-Chloro-5-fluoro-4-methoxyaniline was prepared according to the procedure described in Sielecki-Dzurdz, T. M.; Arvanitis, A. G.; Dzierba, C. D. Pyridino and pyrimidino pyrazinones for treatment of anxiety and depression. World Patent Appl. WO 2004031189-A1, 2004.
42. 5-Amino-4-chloro-2-methylbenzonitrile 26 was prepared by nitration of 4-chloro-2-methylbenzonitrile followed by reduction of the nitro group. (Chemical Equation Presented)
43. Pharmacokinetic parameters were derived noncompartmentally.
44. Oleoyl macrogolglycerides, also known as LabrafilM1944CS, was purchased from Gattefossé, 36 Chemin de Genas, BP 603, 69804 Saint-Priest, France (http://www.gattefossecanada.ca/en/products/pharmaceutical/gattefosse-oral. shtml).
45. Takahashi, L. K.; Kalin, N. H.; VandenBurgt, J. A.; Sherman, J. E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. 1989, 103, 648-654.
46. Li, Y.-W.; Hill, G.; Wong, H.; Kelly, N.; Ward, K.; Pierdomenico, M.; Ren, S.; Gilligan, P.; Grossman, S.; Trainor, G.; Taub, R.; McElroy, J.; Zaczek, R. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolyic efficacy. J. Pharmacol. Exp. Ther. 2003, 305, 86-96.
47. 2 receptor binding assay.
48. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, M.; Jones, B. C.; MacIntyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther. 1997, 283, 46-58.